Thursday, April 02, 2015 3:58:42 PM
NASDAQ Elite has already "run the numbers". Nasrat already has an idea of what each opioid is worth. Those numbers he threw out there a couple of years ago were conservative at best. shares outstanding are not much more than they were back when he made that statement.
If each ADT/ART opioid is worth between $4-$5 per share then I highly doubt that Elite will sell itself for cheap.
The ADT/ART opioids will vary so lets even become more conservative. Say $3 per share. Times just 7 opioids about $21 per share. Now add in all of Elites IP and assets such as generics and non generic.
$21 per share. I would take that offer but nothing less.
With 10 more opioids and a plethora of other applications for their two bead technology..... That would be my bottom figure.
Nasrat has the experience to know what the average value of each ADT/ART is. He has been in the business for what? 30 years?
Yeah NASDAQ, it has the chance to be some real fun for us longs.
If each ADT/ART opioid is worth between $4-$5 per share then I highly doubt that Elite will sell itself for cheap.
The ADT/ART opioids will vary so lets even become more conservative. Say $3 per share. Times just 7 opioids about $21 per share. Now add in all of Elites IP and assets such as generics and non generic.
$21 per share. I would take that offer but nothing less.
With 10 more opioids and a plethora of other applications for their two bead technology..... That would be my bottom figure.
Nasrat has the experience to know what the average value of each ADT/ART is. He has been in the business for what? 30 years?
Yeah NASDAQ, it has the chance to be some real fun for us longs.
Recent ELTP News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/01/2026 11:00:24 AM
- Elite Pharmaceuticals Announces Filing of Abbreviated New Drug Application with the U.S. Food and Drug Administration for Generic Anticoagulant Product • Newsfile • 06/01/2026 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 12:05:23 PM
- Elite Pharmaceuticals Announces Commercial Launch of Methadone Hydrochloride Tablets • Newsfile • 04/02/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/17/2026 10:10:32 PM
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2026 (three months ended December 31, 2025) and Provides Conference Call Information • Newsfile • 02/17/2026 09:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:06:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/11/2026 09:35:26 PM
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2026 Financial Results on February 18, 2026 • Newsfile • 02/11/2026 09:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2026 09:35:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2025 10:10:23 PM
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2026 Ended September 30, 2025 and Provides Conference Call Information • Newsfile • 11/14/2025 09:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:11:38 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 11/12/2025 10:19:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/12/2025 12:15:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/10/2025 12:15:46 PM
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2026 Financial Results on November 17, 2025 • Newsfile • 11/10/2025 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/26/2025 09:17:39 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/22/2025 01:39:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2025 08:37:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2025 08:35:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/25/2025 10:05:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/10/2025 08:17:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/08/2025 08:15:11 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/08/2025 02:58:10 PM
